Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis

Authors

  • Shuai Fu Department of Pharmacy, The People’s Hospital of Danyang, Danyang, Jiangsu, China
  • Jiguang Lu Department of Pharmacy, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu, China
  • Qinwen Zhu Department of Pharmacy, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu, China
  • Bin Yang Department of ENT, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu, China
  • Zhiwei Liu Department of Pharmacy, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China
  • Xinyan Liu Department of Pharmacy, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu, China
  • Jinglin Tian Department of Pharmacy, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu, China

DOI:

https://doi.org/10.18502/ijaai.v25i6.22646

Keywords:

Allergic rhinitis; Efficacy; Omalizumab

Abstract

This meta-analysis was conducted to investigate the efficacy and safety of omalizumab in the treatment of allergic rhinitis in adults.

Randomized controlled trials (RCTs) on omalizumab in the treatment of allergic rhinitis in adults were collected by searching PubMed, Cochrane Library, Embase, Web of Science, CNKI, VIP, and Wanfang Data. The search period was from the establishment of each database to October 2024. Stata 15.0 software was used for data analysis. The control group received a placebo or other anti-allergy drugs, while the experimental group received omalizumab, with or without specific immunotherapy.

A total of 8 RCTs were involved in this meta-analysis. The combined analysis exhibited that the effective rate was higher in the omalizumab group than in the control group (RR=1.15; 95% CI, 1.06–1.24) for allergic rhinitis. IgE levels (SMD=−2.82; 95% CI, −4.03 to −1.62) and DNSS (SMD=−1.99; 95% CI, −3.04 to −0.94), DOSS (SMD=−2.95; 95% CI, −4.65 to −1.25) were lower in the omalizumab group compared with the control group. No significant difference was observed in the incidence of adverse events between the two groups (RR=1.15; 95% CI, 0.69–1.93).

Omalizumab is effective and safe in the treatment of adult allergic rhinitis.

Published

2026-09-15

Issue

Volume (25) issue (6)

Section

Articles